Ann Ibd. Pg. Med 2017. Vol.15, No.2
DISEASE REVIEW
MONKEYPOX
Adebayo O.1 and Owoeye D. 2
1. Department of Medicine, University College Hospital, Ibadan, Nigeria
2. Infection Prevention and Control Directorate, Jazan, Kingdom of Saudi Arabia
INTRODUCTION
Monkeypox is a rare zoonotic disease that occurs
sporadically in Sub Saharan Africa and known to cause
clinically indistinguishable disease from other pox
diseases especially smallpox.1,2
The minority of cases occur through human-to-human
transmission and rarely beyond two generations. As
much as 80% of cases occur through animal to human
transmission.5,12
The disease was first discovered in 1958 among sick
monkeys (Macaca cynomolgus) originating from Singapore
and isolated at the State Serum Institute in Copenhagen,
Denmark; however, the first human case was
discovered in 1970 in a child in Equateur region of
Republic of Congo (formerly Zaire).3-7 It has largely
been believed its epidemiology was masked by
smallpox transmission and the eradication of smallpox
in 1977 brought the disease to prominence.1,8 It is also
expected that as the immunity for small pox virus wane
in the population, the risk for monkeypox virus will
increase.9 The virus has potential of being used as a
bioterrorism agent.
Virology
Monkeypox virus (MPV) belong to genus
orthopoxvirus of Poxviridae family (subfamilyChordopoxvirinae).6 Other members of orthopoxvirus include Cowpox virus and Variola virus which
causes cowpox and small pox diseases respectively.
Monkeypox virus (MPV) is closely related to Variola
virus (about 90% genome homology).11
Epidemiology
The disease s burden is largely concentrated in rural &
near tropical rain forest of Central and Western Africa,
although outbreaks have been reported in other part
of the world especially United States.5 The affected
communities are also noted to be impoverished and
generally have a high prevalence background of
parasitic infections, malnutrition, and other significant
heath-compromising conditions.10 There is no racial
or gender predilection.
Transmission
It primarily infects animals and from animals can be
transmitted to humans through: direct contact from
the bite or scratch of an infected animal; direct contact
with muco-cutaneous lesions of infected animals; direct
contact with the infected animals blood, body fluids
or secretions (when these comes in contact with the
blood of humans through exposed wounds or injuries
or direct transfusion) or indirect contact with materials
contaminated with the blood and body secretions of
the infected animals.5,13
It is a single molecule of double stranded DNA and
have two major genetic clades of the virus; the lesser
virulent clade occurring in West Africa and the other
in Central Africa.10
The disease is endemic in Democratic Republic of
the Congo (DRC) (also Zaire) while it occurs
sporadically in other part.5 Crude incidence rate of
5.53 per 10,000 people have been reported in DRC
with most of the affected people below 15years.5,11
Some other countries where the disease has been
reported include Cameroon, Central African Republic,
Liberia, Nigeria, and Sierra Leone.5,10
It can also be transmitted from humans to humans i.e.
secondary infection through inhaling the respiratory
droplets (close contact is needed) of an infected person,
direct contact with the blood or body fluids of
infected person or indirect contact with materials
contaminated with the blood or body fluids of
infected person.5,13
The most likely reservoir of the disease is the rodent.
1,9
Other possible sources of the infection include
squirrels - Funiscuirus spp., sooty mangabey - Cercocebus
spp., sun squirrels - Heliosciurus spp., giant pouched rats
- Cricetomys spp., brush-tailed porcupines - Atherurus spp.,
African dormice - Graphiurus spp., and West African
Hybomys or temminck s striped Mouse-Hybomys spp.,
rope squirrels, tree squirrels, Gambian rats, striped mice
and pet prairie dogs (Cynomys species).5
Pathogenesis and Pathology
MPV gains entrance through a break in the mucocutaneous layer or the respiratory linings and migrate
through the lymphatic system during primary viraemia,
subsequently proliferating in the lymphoid tissue i.e.
spleen, bone marrow, and lymph nodes. 14,15 The
invasion prompts cytotoxic T cell immune activation.
MPV proliferates in the macrophages where it
disseminates through the vessels to other parts of the
Annals of Ibadan Postgraduate Medicine. Vol. 15 No. 2, December 2017
145
body during secondary viraemia. 14 It localizes within
the vessels in the dermis and subsequently invade the
epidermis.14 It initiates necrosis and oedema of the
skin layer.
The commonest histologic features of monkey pox
are cellular proliferation causing thickening of skin
(acanthosis), necrosis, degeneration, blister generation
and inflammation in the lesion.15,16 There is intracellular
oedema (spongiosis) arising from inflammatory
processes in the lesion too.16
Clinical features
The incubation period is 10 14 days.1 The disease is
usually infectious within first one week of its onset.1
It is characterized by rash which is preceded by 2 days
prodrome of fever and severe lymphadenopathy.1 The
rash initially start as maculo-papular of 2 5 mm in
diameter then progresses through papular, vesicular,
pustular, and crust phases over a period of 14 21
days.1(See figure 1&2) The rashes are in most cases
monomorphic but in other cases pleomorphic with
number of lesion reaching as much as 500 and average
lesion being 100. 10 In an article by Reynolds et al, the
spectrum of rash using lesions count was graded to
be:
(i) Benign: 5 25 lesions with ocular involvement.
(ii) Moderate: 26
100 lesions with ocular
involvement.
(iii) Grave: 101 250 lesions with lymphadenopathy.
(iv) Plus grave: above 250 lesions. 10
The rashes are mainly on the face, sole of feet and
palm of the hands.5 The rashes subsequently slough
off and heal as depigmented scar. 1 Other
manifestations include intense headache, chills, lack of
appetite and back pain. 2 In addition, there are
respiratory symptoms and conjunctivitis. 4,10
Figure 1: Clinical picture of Monkeypox rash.
Image credit: CDC https://www.cdc.gov/poxvirus/
monkeypox/index.html
Differential diagnosis
The infection is similar, but milder than, human
smallpox or chickenpox. The differential diagnoses
include smallpox, chickenpox, drug eruptions,
herpetiformis, rickettsial pox, eczema herpeticum,
dermatitis and molluscum contagiosum, bacterial skin
In the early phase of the disease there is intense asthenia
and myalgia. The lymphadenopathy which is a
prominent feature can affect the submandibular,
cervical, postauricular, axillary, or inguinal lymph
nodes.1 It is difficult to clinically distinguish from other
pox like diseases such as smallpox and chicken pox.
The disease can be fatal in 1-10% of cases.5
Furthermore the disease can be asymptomatic.
Diagnosis
The virus can be detected through enzyme-linked
immunosorbent assay (ELISA), antigen detection tests,
polymerase chain reaction (PCR) assay and virus
isolation by cell culture.5
Figure 2: Clinical picture of Monkeypox rash.
Image credit: CDC https://www.cdc.gov/poxvirus/
monkeypox/index.html
Annals of Ibadan Postgraduate Medicine. Vol. 15 No. 2, December 2017
146
infections, scabies, syphilis, and drug-associated
allergies. 5,17 Smallpox does not produce marked
lymphadenopathy as seen in monkeypox while the rash
distribution in chicken pox is mainly on the trunk and
in different stages of development in contrast to
monkeypox.1,4
Treatment
There is no licensed specific cure for monkeypox.
Prognosis
It is a self-limiting disease with severe disease usually
in children.5
Control and prevention
The wide number of hosts of MPV has made its
eradication difficult. 1 There is no vaccine against
monkeypox although smallpox vaccine was found to
be 85% effective.5 Though the vaccine is not publically
available, Center for Disease Control and Prevention
(CDC) recommends its use two weeks of exposure
to source of infection.
There are two aspects to preventing this disease which
includes curtailing animal to human transmission and
human to human transmission. Ensuring standard
precaution plays a very important role in prevention
and control of monkeypox transmission.13
Specifically the prevention and control entail avoiding
contact with the infected hosts (animals and humans)
and consumption of the identified animals, ensuring
meats of reservoirs are well cooked, performing hand
hygiene routinely with either soap and clean flowing
water or alcohol gel, perform it before and after
contact with any suspected ill person or when in
hospital environment and in the community, ensure
performing other safety precautions like respiratory
hygiene, using appropriate personal protective
equipment when in presence of suspected or infected
people coughing, talking or sneezing and operating an
adequate disease surveillance system.5,13
The use of airborne precaution is recommended for
examining and admission of patient due to the risk of
airborne transmission of the disease.18 Patients, at the
point of entry to the health facility, are identified as
suspected cases through respiratory visual triage (a
visual triage to identify people with infectious
respiratory illnesses by their clinical features) and face
mask is given to patient and accompanying person
(family, friends or others) while patients waiting room
for all respiratory infections should have seats separated
1m apart.19 Ideally, patient should be examined and
admitted in an air negative pressure isolation room
with adherence to airborne precautions; fully protective
covering with gloves, gown, air respirator (mostly
N95), face shield is used, notice of airborne precaution
with necessary informative infection control measures
fixed on the door of the isolation room. When an air
negative pressure room is not available, single isolation
room can be a substitute.18 The movement of patient
from the point of reception to the admission room
should be limited to less contact and areas with no
crowding to control MPV spread. Minimal number
of care givers trained on infection control should be
assigned to patient and family members or friends
visiting patient should be reduced to only those needed
to offer care and support. A log book of inflow and
outflow of people into the isolation room with
presence of symptoms peculiar to monkey pox disease
should be kept for tracking secondary infections among
all contacts.19
Health education of animal handlers and continuous
training of health workers to help raise clinical high
index of suspicion is very important.
REFERENCES
1. Di Giulio DB, Eckburg PB. Human monkeypox:
an emerging zoonosis. The Lancet Infectious
diseases 2004; 4:15-25.
2. Huhn GD, Bauer AM, Yorita K, et al. Clinical
characteristics of human monkeypox, and risk
factors for severe disease. Clinical infectious
diseases : an official publication of the Infectious
Diseases Society of America 2005; 41:1742-1751.
3. Ladnyj ID, Ziegler P, Kima E. A human infection
caused by monkeypox virus in Basankusu Territory,
Democratic Republic of the Congo. Bulletin of
the World Health Organization 1972; 46:593-597.
4. Heymann DL, Szczeniowski M, Esteves K. Reemergence of monkeypox in Africa: a review of
the past six years. British medical bulletin 1998;
54:693-702.
5. Monkeypox. World Health Organisation, 2017.
(Accessed 27th December 2017, 2017, at http://
www.who.int/mediacentre/factsheets/fs161/en/
.)
6. Pal M, Mengstie F, V. K. Epidemiology,
Diagnosis, and Control of Monkeypox Disease:
A comprehensive Review. . American Journal of
Infectious Diseases and Microbiology 2017; 5:9499.
7. Usman S, II A. Modeling the Transmission
Dynamics of the Monkeypox Virus Infection with
Treatment and Vaccination Interventions. Journal
of Applied Mathematics and Physics 2017;5:2335.
8. Parker S, Nuara A, Buller RM, Schultz DA.
Human monkeypox: an emerging zoonotic
disease. Future microbiology 2007; 2:17-34.
Annals of Ibadan Postgraduate Medicine. Vol. 15 No. 2, December 2017
147
9. Fred W. Molluscum Contagiosum,Monkeypox
and other Poxvirus infections. In: DL L, AS F,
DL K, HauserSL, Jamerson J, J L, eds. Harrison s
Principle of Internal Medicine. 18th ed: McGraw
Hill Medical; 2012:1476-1478.
10. Reynolds MG, McCollum AM, Nguete B,
Shongo Lushima R, et al. Improving the Care and
Treatment of Monkeypox Patients in LowResource Settings: Applying Evidence from
Contemporary Biomedical and Smallpox
Biodefense Research. Viruses 2017;9.
11. Quiner CA, Moses C, Monroe BP, et al.
Presumptive risk factors for monkeypox in rural
communities in the Democratic Republic of the
Congo. PloS one 2017;12:e0168664.
12. Arita I, Jezek Z, Khodakevich L, Ruti K. Human
monkeypox: a newly emerged orthopoxvirus
zoonosis in the tropical rain forests of Africa. The
American journal of tropical medicine and hygiene
1985; 34:781-789.
13. Adebayo O, Labiran A, Imarhaigbe L. Standard
Precautions in Clinical Practices: A Review.
14.
15.
16.
17.
18.
19.
International Journal of Health Sciences and
Research 2015;5:521-528.
Monkey pox virus. (Accessed 22Dec 2017, 2017,
at https://vir us.stanford.edu/pox/2000/
monkeypox_virus.html )
Wenner HA, Bolano CR, Cho CT, Kamitsuka
PS. Studies on the pathogenesis of monkey pox.
3. Histopathological lesions and sites of immunofluorescence. Archiv fur die gesamte Virusforschung 1969; 27:179-197.
Weedon D. Monkeypox. Weedon s Skin
Pathology. third edition ed: Churchill Livingstone;
2010.
Breman JG. Monkeypox: an emerging infection
for humans?. Emerging infections 2000;4:45-67.
Infection Control: Hospital. 2015. (Accessed 27th
December 2017, 2017, at https://www.cdc.gov/
poxvirus/monkeypox/clinicians/infectioncontrol-hospital.html.)
Infection prevention & control manual. (Accessed
27th December 2017, at https://www.interior
health.ca/AboutUs/QualityCare/IPCManual/
Entire%20Infection%20Control%20Manual.pdf.)
Annals of Ibadan Postgraduate Medicine. Vol. 15 No. 2, December 2017
148